Helix BioPharma Corp. Extends Annual Meeting Date
January 28 2019 - 7:30AM
Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), an
immuno-oncology company developing innovative drug candidates for
the prevention and treatment of cancer, today announced that it has
received consent from the Toronto Stock Exchange to extend the date
of its annual general meeting of shareholders to a date not later
than April 18, 2019. The Company made the request to extend the
date of the annual general meeting of shareholders as a result of
ongoing discussions to divest a majority stake in its wholly owned
Polish subsidiary, Helix Immuno-Oncology S.A., which the Company
expects to put to a vote for shareholder approval. Helix
expects that the directors will call an annual meeting of
shareholders in the coming weeks.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology
company specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix’s
product development initiatives include its novel L-DOS47 new drug
candidate and Chimeric Antigen Receptor (“CAR”) based cell
therapies. Helix is currently listed on the TSX and FSE under the
symbol “HBP”.
Investor Relations
Helix BioPharma Corp.9120 Leslie Street, Suite
205Richmond Hill, Ontario, L4B 3J9Tel: 905-841-2300Email:
ir@helixbiopharma.com
Cautionary Statements
This news release may contain forward-looking
statements and information (collectively, “forward-looking
statements”) within the meaning of applicable Canadian securities
laws, including, without limitation, those relating to Helix’s
operations and strategy, its research and development activities
and statements regarding the expected use of net proceeds of the
private placement. Forward-looking statements, which may be
identified by words including, “without limitation”, “believe”,
“subject to”, “will”, “should” “may”, “promising” and other similar
expressions, are intended to provide information about management’s
current plans and expectations.
Although Helix believes that the expectations
reflected in such forward-looking statements are reasonable, such
statements involve risks and uncertainties that may cause actual
results or events to differ materially from those anticipated and
no assurance can be given that these expectations will be realized,
and undue reliance should not be placed on such statements. Risk
factors that could cause actual results or events to differ
materially from the forward-looking statements include, without
limitation, risks inherent in Helix’s research and development
activities and those risks and uncertainties affecting the company,
as more fully described in Helix’s most recent Annual Information
Form, including under the headings “Forward-Looking Statements” and
“Risk Factors”, filed under Helix’s profile on SEDAR at
www.sedar.com (together, the “Helix Risk Factors”). Certain
material factors or assumptions are applied in making the
forward-looking statements, including, without limitation, that the
factors described in the Helix Risk Factors will not cause Helix’s
actual results or events to differ materially from the
forward-looking statements. These cautionary statements qualify all
such forward-looking statements.
Forward-looking statements and information are
based on the beliefs, assumptions and expectations of Helix’s
management on the date of this news release, and Helix does not
assume any obligation to update any forward-looking statement or
information should those beliefs, assumptions or expectations, or
other circumstances change, except as required by law.
Helix BioPharma (TSX:HBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
From Jul 2023 to Jul 2024